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Abstract 
Objective: To compare the efficacy of oxitard and lycopene in the management of Oral 
Submucous Fibrosis (OSMF). Material and Methods: 120 subjects with clinic-
pathologically diagnosed OSMF were included in the study and divided equally in 2 
groups, Group A (oxitard) and Group B (lycopene). Group A was administered 2 oxitard 
capsules twice daily and Group B was given 8 mg lycopene in 2 divided doses of 4 mg 
for 3 months. Gingival index and plaque index were documented for all patients and 
compared. Evaluation for different clinical parameters was done at regular intervals and 
data was analyzed using the Student’s paired t test and Chi-square test. P-value <0.001 
was considered to be statistically significant. Results: Clinical improvements in mouth 
opening and tongue protrusion was significant in Group A (p<0.001). Subjective 
symptoms of pain associated with the lesion (p=0.0001), difficulty in swallowing 
(p=0.0004) and speech (p=0.0002) significantly improved in the Group A. However, 
there was no significant improvement in burning sensation (p>0.001) among the 2 
groups. Although the mean gingival index and plaque index in group A was reduced but 
it was found to be not statistically significant. Conclusion: Oxitard capsules can bring 
about significant clinical improvements in the symptoms like mouth opening, tongue 
protrusion, difficulty in swallowing and speech and pain associated with the lesion when 
compared to lycopene, thereby improving the quality of life of the affected individuals. 
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Introduction 
Oral submucous fibrosis (OSMF) is a potentially malignant disorder of oral cavity, pharynx 
and upper digestive tract, characterized by progressive inability to open the mouth and by 
inflammation and progressive fibrosis of the submucosal tissues [1]. The pathogenesis of the disease 
is not well known, but the etiology is believed to be multifactorial. The condition is particularly 
associated with areca nut chewing, which is the main component of betel quid. The habit of betel 
quid chewing is practiced predominately in the Indian subcontinent from a long time [2]. 
The ingredients of arecanut induce excessive reactive oxygen species, which damages the cell 
structures [3]. Accompanied with this, vitamin deficiency, iron deficiency anemia, and poor nutrition 
can disturb the repair of the inflamed oral mucosa, leading to poor healing. This results in atrophic 
oral mucosa, which becomes more susceptible to the effects of areca nut. The antioxidant vitamins 
are thus employed to stabilize and deactivate the free radicals before they attack cells [4]. 
Treatment modalities for relieving the symptoms have been advocated, but have not been 
successful so far. The first step of preventive measure should be in discontinuation of habit, which 
can be encouraged through education, counseling and advocacy and to maintain proper oral hygiene. 
Medical treatment is symptomatic and predominantly aimed at improving mouth movements. 
Specific treatment includes administration of steroids, placental extracts, IFN gamma, pentoxifylline, 
lycopene, surgical excision, etc [2-5]. Oxitard capsules have been successfully tried in the treatment 
of OSMF [6]. Lycopene has also been proved to be the most potent radical scavenger in various 
studies and it has been tried in the treatment of leukoplakia and also in OSMF [7,8]. But each 
treatment has its own limitations. The present study was carried out to compare the efficacy of these 
newer antioxidants in the management of oral submucous fibrosis. 
 
Material and Methods 
Study Design and Data Collection 
The present prospective study included 120 subjects with clinico-pathologically diagnosed 
OSMF reporting to the Department of Oral Medicine and Radiology, Jodhpur Dental College 
General Hospital. Patients of either gender with OSMF were included in the study. Those with any 
evidence of severe psychiatric, cardiac, gastrointestinal or metabolic disorders and pregnancy and 
lactation were excluded from the study. Detailed family and medical history with a history of 
associated habits and the course of the disease was recorded.  
A thorough clinical examination was carried out and relevant findings were recorded. The 
subjects were randomly divided equally in 2 groups, Group A (Oxitard) and Group B (Lycopene). 
Group A was administered 2 oxitard capsules twice daily and Group B was given 8 mg lycopene 
(LycoredTM, Jagsonpal Pharmaceuticals, New Delhi, India) in 2 divided doses of 4 mg for 3 months. 
Mouth opening was measured by measuring the distance between the centre of incisal edges 
of maxillary central incisors and mandibular central incisor at maximum opened mouth. In 
edentulous patients, the inter ridge (alveolar) distance along the midline was measured. Three 
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measurements were recorded consecutively and the average value was calculated and recorded. 
Tongue protrusion was measured as distance between lower central incisor and tip of the tongue on 
protrusion. 
Evaluation for presence, absence or reduction of other clinical parameters such as burning 
sensation, pain associated with the lesion, difficulty in swallowing and speech was done at regular 
intervals of 1 month, 2 month and 3 months. Gingival index [9] and plaque index [10] was 
recorded before and after the treatment for each patient in both groups. 
 
Data Analysis 
The data was entered using computer software IBM SPSS Statistics for Windows version 20 
(IBM Corp., Armonk, NY, USA) and analyzed using the Student’s paired t test and Chi-square test. 
P-value<0.001 was considered to be statistically significant. 
 
Ethical Aspects 
Ethical clearance was obtained from the Institutional Ethical Committee of Jodhpur Dental 
College, Jodhpur National University. A written informed consent was obtained from all the 
participants prior to the inclusion in the study. 
 
Results 
There were 64 males and 56 females with a mean age of 31.6±12.7 years. 56% of the patients 
had habit of betel nut chewing, while 26% of the patients had tobacco chewing habit. 40% of the 
patients consumed spicy foods, which were among the main causative factors for OSMF in the study 
population. Clinical improvements in mouth opening and tongue protrusion was significant in the 
Group A (p<0.001) (Tables 1 and 2). 
 
Table 1. Effect of oxitard and lycopene in improving mouth opening (mean values in mm). 
Evaluation Oxitard Lycopene  p-value 
Baseline 19.1±2.4 18.2±2.1  
<0.001 After 1 month 21.6±2.6 20.2±2.2 
After 2 months 27.2±2.9 22.4±2.5 
After 3 months 31.5±2.9 25.9±2.3 
 
Table 2. Effect of oxitard and lycopene in improving tongue protrusion (mean values in mm). 
Evaluation Oxitard Lycopene p-value 
Baseline 10.1±1.4 9.8±2.1  
<0.001 After 1 month 13.6±2.4 10.3±1.9 
After 2 months 20.2±2.1 15.7±2.2 
After 3 months 24.5±2.5 19.1±1.9 
 
The effect of administration of oxitard capsules in the Group A showed significant 
improvement in the subjective symptoms of pain associated with the lesion (p=0.0001), difficulty in 
swallowing (p=0.0004) and speech (p=0.0002) when compared to the Group B who were given 
lycopene (Tables 3 to 5). 
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Table 3. Effect of oxitard and lycopene on pain associated with pain. 
 Oxitard Lycopene 
Evaluation Present Absent Reduced Present Absent Reduced 
Baseline 58 2 - 59 1 - 
After 1 month 50 4 6 53 4 5 
After 2 months 29 17 14 35 11 14 
After 3 months 11 31 18 24 25 11 
 
 
Table 4. Effect of oxitard and lycopene on difficulty in swallowing. 
 Oxitard Lycopene  
Evaluation Present Absent Reduced Present Absent Reduced 
Baseline 57 3 - 58 2 - 
After 1 month 38 10 12 50 4 6 
After 2 months 24 22 14 36 11 13 
After 3 months 7 36 17 23 25 12 
 
 
Table 5. Effect of oxitard and lycopene on difficulty in speech. 
 Oxitard Lycopene  
Evaluation Present Absent Reduced Present Absent Reduced 
Baseline 56 4 - 57 3 - 
After 1 month 36 14 10 41 9 10 
After 2 months 22 24 14 32 19 9 
After 3 months 10 38 12 18 28 14 
 
However, there was no significant improvement in burning sensation (p>0.001) among the 2 
groups (Table 6). Eight patients experienced mild abdominal discomfort due to oxitard. There were 
no reported side effects of lycopene. None of the patients withdrew from the study due to any reason. 
 
Table 6. Effect of oxitard and lycopene on burning sensation. 
 Oxitard Lycopene 
Evaluation Present Absent Reduced Present Absent Reduced 
Baseline 60 - - 60 - - 
After 1 month 42 8 10 48 3 9 
After 2 months 28 18 14 30 12 18 
After 3 months 3 43 14 7 32 21 
 
Table 7 shows a decreased accumulation of plaque, improvement in the gingival health but 
these findings were statistically non-significant. 
 
Table 7. Comparison of the mean plaque index and gingival index. 
 Group A Group B 
Variables Baseline 
(mean±SD) 
3 months 
(mean ± SD) 
t-value p-value Baseline 
(mean±SD) 
3 months 
(mean ± SD) 
t-value p-value 
Plaque 
Index 
2.32 ± 0.50 
(1.17 – 3.00) 
2.30 ± 0.51 
(1.08 – 3.00) 
- 1.81 0.075 2.31 ± 0.48 
(1.21 – 2.92) 
2.28 ± 0.48 
(1.25 – 2.96) 
-1.84 0.071 
Gingival 
Index 
2.18 ± 0.24 
(1.67 – 2.71) 
2.16 ± 0.23 
(1.58 – 2.58) 
-1.71 0.093 2.24 ± 0.23 
(1.75 – 2.79) 
2.21 ± 0.24 
(1.71 – 2.75) 
-1.98 0.052 
SD = Standard Deviation. 
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Discussion 
Treatment modalities for relieving the symptoms related to oral submucous fibrosis (OSMF) 
have been advocated, but have not been successful so far [11-15]. The first step of preventive 
measure should be in advising the patient to discontinue the habit of betel nut chewing, tobacco, 
spicy foods and chillies. This can be encouraged through education, counseling and advocacy. 
Medical treatment is symptomatic and predominantly aimed at improving mouth movements. But 
each treatment has its own limitations [16,17]. 
The medical management of oral submucous fibrosis is both empirical and unsatisfactory 
[13]. Multiple minerals and micronutrients showed significant improvement in mouth opening of 
41% of the patients [18]. Whereas, some authors showed improvement in symptoms of OSMF but 
insignificant improvement in mouth opening with vitamin A [19]. Lycopene has also showed 
significant improvement in mouth opening [8]. Previous study has shown significant improvement 
in mouth opening, hyperkeratosis, pain in mouth and size of the lesion with oxitard capsules [6]. 
However, the present study compared the efficacy of the 2 newer antioxidants oxitard and lycopene 
in the improvement of clinical parameters such as, difficulty in swallowing, speech, tongue 
protrusion and burning sensation.  
Lycopene is a major carotenoid obtained from tomato, which has potent anticancer activity 
[20]. The antioxidant properties of lycopene in various types of cancers are thought to be primarily 
involved in its preventive effects in chronic diseases. It also has potent benefits in oral potentially 
malignant lesions like leukoplakia. Because of its high number of conjugated dienes, lycopene is one 
of the most potent antioxidants, with a singlet-oxygen-quenching ability twice as high as that of β-
carotene and 10 times higher than that of α-tocopherol [21]. New findings have reported the 
anticancer activity of lycopene is due to the upregulation of connexin 43 and stimulation of gap 
junctional communication that does not involve its role as an antioxidant [9]. 
The formulation of the oxitard capsules contains the extracts of Mangifera indica, Withania 
somnifera, Daucus carota, Glycyrrhiza glabra, Vitis vinifera, powders of Emblica officinalis and Yashada 
bhasma; and oils of Triticum sativum. Mangifera indica is shown to have antibiotic, anti-asthamatic, 
antiseptic, antiviral, hypotensive, anti-emetic properties. Withania somnifera provides overall health 
and wellness with its anti-stress, anti-anxiety, anti-inflammatory, anti-convulsive and anti-arthritic 
properties. Daucus carota acts as a good antiseptic as it is a rich source of vitamin A. Glycyrrhiza 
glabra normalizes the hoarseness in voice and has immunomodulatory and anti-inflammatory 
properties. Vitis vinifera have anti-inflammatory, astringent and an effect to curb the burning 
sensation. Emblica officinalis is a rich source of vitamin C and is a potent antibiotic. Yashada bhasma 
contains zinc, which plays a significant role in protein synthesis, cell division and wound healing. 
Triticum sativum is a rich source of minerals and has an antioxidant property [7]. 
There was a significant (p<0.001) improvement in the mouth opening and tongue protrusion 
in the patients who were administered oxitard capsules when compared to those who were given 
lycopene softgel orally. This was similar to previous findings that observed a significant 
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improvement in the mouth opening of the patients who were given oxitard capsules [6]. It was 
observed significant improvement in mouth opening in the lycopene group [8,9]. Improvement in 
mouth opening is not only due to habit intervention but also due to the antioxidant drugs. Although, 
the mechanism leading to reduced mouth opening is still unclear, it can be due to fibrosis and fibrous 
band formation in the oral mucosa [9].  
Tongue protrusion also showed improvement in both the groups, but Group A showed more 
significant improvements (p<0.001). A significant improvement was observed in the tolerance to 
burning sensation in both the groups. However, Group A showed more improvement but the 
difference between the 2 groups was statistically insignificant (p>0.001). The effect of administration 
of oxitard capsules in the Group A showed significant improvement in the subjective symptoms of 
pain associated with the lesion (p=0.0001), difficulty in swallowing (p=0.0004) and speech 
(p=0.0002) when compared to the Group B who were given lycopene. 
Studies in the literature have shown the influence of betel nut chewing on the periodontium 
and it has been proposed that the physical action of the components of the betel nut could be the 
etiological factor [15]. In the present study, improvement in gingival index and plaque index was 
observed in group A when compared to group B, but these differences were statistically non 
significant. The improvement in these parameters in the present study could be attributed to the 
improvement in mouth opening and decrease in pain. 
The findings of the present study demonstrate that oxitard capsules are more effective than 
lycopene as an antioxidant given as the first line of treatment in oral submucous fibrosis. There were 
improvements in both the groups but significant improvements were observed in the Group A. A 
larger study with larger sample size and longer follow-up period is encouraged to get more accuracy 
in the efficacy of the antioxidants. 
 
Conclusion 
Oxitard was seen more efficacious antioxidant than lycopene in the management of oral 
submucous fibrosis. In contrast to other treatment modalities, these drugs offer a non-invasive 
treatment option with significant improvements in mouth opening, tongue protrusion, burning 
sensation, difficulty in swallowing and speech. Hence, oxitard is more preferable than lycopene in the 
management and control of the progression of this chronic debilitating condition of the Indian sub-
continent. 
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